MATERIAL SAFETY. CyDex shall provide Hospira, in writing, from time to time, with (a) relevant material information currently known to it regarding handling precautions, toxicity and hazards with respect to Captisol, and (b) the then-current material safety data sheet for Captisol. Hospira is solely responsible for (i) any Finished Product regulatory submission to the FDA or any other Regulatory Authority, and (ii) determining the suitability of any documentation provided by CyDex hereunder for use in any such regulatory submission.
Appears in 2 contracts
Sources: License and Supply Agreement (Ligand Pharmaceuticals Inc), License and Supply Agreement (Ligand Pharmaceuticals Inc)